NL-OMON37167招募中不适用
Adoptive T cell therapy plus vaccination in metastatic melanoma patients - ACT in melanoma.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Age >= 18 years.
- •2. Histologically proven melanoma.
- •3. Melanoma must be at one of the following AJCC 2009 stages:
- •-Irresectable (or residual) regional metastatic melanoma, i.e. in terms of AJCC 2009 classification irresectable stage III melanoma, or
- •-Stage IV melanoma, i.e. distant metastatic disease (any T, any N, M1a, M1b or M1c), and normal LDH.
- •4. Patients with brain metastases have to be neurologically stable for at least 2 months and should not use dexamethasone.
- •5. Presence of measurable progressive disease according to RECIST version 1.1.
- •6. Expected survival of at least 3 months.
- •7. WHO performance status <=1.
- •8. Within the last 2 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified :
- •Lab Parameter Range
- •Hemoglobin >= 6,0 mmol/l
- •Granulocytes >= 1,500/µl
- •Lymphocytes >= 700/µl
- •Platelets >= 100,000/µl
- •Creatinine clearance >= 60 min/ml
- •Serum bilirubin <= 40 µmol/l
- •ASAT and ALAT <= 5 x the normal upper limit
- •LDH <= 2 x the normal upper limit
- •9. Viral tests:
- •-Negative for HIV type 1/2, HTLV and TPHA
- •-No HBV (hepatitis B virus) antigen or antibodies against HBc in the serum
- •-No antibodies against HCV (hepatitis C virus) in the serum
- •10. Able and willing to give valid written informed consent.
- •11. Prior treatment, including immunotherapy e.g. with Ipilimumab, is allowed but systemic therapy must have been discontinued for at least four weeks before study entry. Radiotherapy and MEK-inhibitor/BRAF-inhibitor should be discontinued for at least two weeks before study entry. Patients should have PD after treatment. After treatment with Ipilimumab initial PD should be confirmed by repeated imaging studies evaluated according to irRC to exclude late effects of Ipilimumab treatment.
排除标准
- •Patients will be excluded from the study for any of the following reasons:;1. Patients with brain metastases who are neurologically unstable and/or on use of dexamethasone.
- •2. Clinically significant heart disease (NYHA Class III or IV).
- •3. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.
- •4. Active immunodeficiency disease or autoimmune disease requiring immune suppressive drugs. Vitiligo is not an exclusion criterion.
- •5. Other malignancy within 2 years prior to entry into the study, except for treated non-melanoma skin cancer and in situ cervical carcinoma.
- •6. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
- •7. Lack of availability for follow-up assessments.
- •8. Pregnancy or breastfeeding.
研究者
相似试验
进行中（未招募）
不适用
T lymphocyte infusions plus vaccination as treatment for melanoma.EUCTR2012-000552-33-NLeiden University Medical Center
招募中
不适用
Adoptive T cell therapy in patients with recurrent ovarian cancerEpithelial Ovarian CancerNL-OMON46501Academisch Medisch Centrum12
进行中（未招募）
1 期
Cell based treatment in combination with checkpoint inhibitors for ovarian-, fallopian tube and primary peritoneal cancer.EUCTR2017-002179-24-DKCenter for Cancer Immune Therapy6
招募中
不适用
Adoptive therapy with TCR gene-engineered T cells to treat patients with MAGE-C2-positive melanoma and head and neck cancer.head and neck squamous cell carcinomamaligne melanomauveal melanoma100300541002765610040900skin cancerNL-OMON52657Erasmus MC, Universitair Medisch Centrum Rotterdam20
招募中
2 期
MAGE-C2 TCR T cell therapy2024-516922-70-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)20